Biotech innovator Alumis, focused on autoimmune therapies, reported a significant insider buy amid a year of robust stock ...
China NMPA approves Sanofi’s Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome: Paris Saturday, January 17, 2026, 11:00 Hrs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback